Prognostic Risk Factors of Carbapenem-Resistant Gram-Negative Bacteria Bloodstream Infection in Immunosuppressed Patients: A 7-Year Retrospective Cohort Study

References

• Zhang P, Wang J, Hu H, et al. Clinical characteristics and risk factors for bloodstream infection due to carbapenem-resistant Klebsiella pneumoniae in patients with hematologic malignancies. Infect Drug Resist. 2020;13:3233–3242. doi:10.2147/IDR.S272217
   Web of Science ®Google Scholar
• Babiker A, Clarke LG, Saul M, et al. Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000–2017. Clin Infect Dis. 2020;73(11):e4521–e4530. doi:10.1093/cid/ciaa1464
   Web of Science ®Google Scholar
• Hu FP China Antimicrobial Surveillance Network, the results of bacterial resistance in 2021[DB/OL]; 2022. Available from: https://www.chinets.com/Document. Accessed October 28, 2022.
   Google Scholar
• Birru M, Woldemariam M, Manilal A, et al. Bacterial profile, antimicrobial susceptibility patterns, and associated factors among bloodstream infection suspected patients attending arba minch general hospital, Ethiopia. Sci Rep. 2021;11:1. doi:10.1038/s41598-021-95314-x
   Web of Science ®Google Scholar
• Wu D, Chen C, Liu T, et al. Epidemiology, susceptibility, and risk factors associated with mortality in carbapenem-resistant gram-negative bacterial infections among abdominal solid organ transplant recipients: a retrospective C. Infect Dis Ther. 2021;10(1):559–573. doi:10.1007/s40121-021-00411-z
   Web of Science ®Google Scholar
• Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. Int J Infect. 2020;81(1):e61–e66. doi:10.1016/j.jinf.2020.04.026
   Web of Science ®Google Scholar
• Azoulay E, Russell L, Louw AV, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 2020;46(2):298–314. doi:10.1007/s00134-019-05906-5
   PubMed Web of Science ®Google Scholar
• Chai J, Han X, Mei Q, et al. Clinical characteristics and mortality of non-tuberculous mycobacterial infection in immunocompromised vs. Immunocompetent Hosts Front Med. 2022;9. doi:10.3389/fmed.2022.884446
   Google Scholar
• Lin H, Yang L, Fang J, et al. Clinical characteristics of bloodstream infection in immunosuppressed patients: a 5-year retrospective cohort study. Front Cell Infect Microbiol. 2022;12. doi:10.3389/fcimb.2022.796656
   Web of Science ®Google Scholar
• Bar-Yoseph H, Cohen N, Korytny A, et al. Risk factors for mortality among carbapenem-resistant enterobacteriaceae carriers with focus on immunosuppression. Int J Infect. 2019;78(2):101–105. doi:10.1016/j.jinf.2018.10.003
   Web of Science ®Google Scholar
• Baier C, Beck M, Panagiota V, et al. Infection control management and surveillance of carbapenem-resistant gram-negative bacteria in hematopoietic stem cell recipients. Antimicrob Resist Infect Control. 2019;8:1. doi:10.1186/s13756-019-0606-3
   Web of Science ®Google Scholar
• Lan P, Lu Y, Chen Z, et al. Emergence of high-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in patients with hematologic malignancies in China. Microbiol Spectr. 2022;10:2. doi:10.1128/spectrum.00084-22
   Web of Science ®Google Scholar
• Leung C-H, Liu C-P. Diabetic status and the relationship of blood glucose to mortality in adults with carbapenem-resistant Acinetobacter baumannii complex bacteremia. J Microbiol Immunol Infect. 2019;52(4):654–662. doi:10.1016/j.jmii.2018.06.005
   Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.002
   PubMed Web of Science ®Google Scholar
• Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70(11):3146–3153. doi:10.1093/jac/dkv218
   PubMed Web of Science ®Google Scholar
• Hu Y, Li D, Xu L, et al. Epidemiology and outcomes of bloodstream infections in severe burn patients: a six-year retrospective study. Antimicrob Resist Infect Control. 2021;10:1. doi:10.1186/s13756-021-00969-w
   Web of Science ®Google Scholar
• Amanati A, Sajedianfard S, Khajeh S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis. 2021;21:1. doi:10.1186/s12879-021-06243-z
   Web of Science ®Google Scholar
• Kim SY, Jung JY, Kang YA, et al. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci. 2012;27(8):939. doi:10.3346/jkms.2012.27.8.939
   Web of Science ®Google Scholar
• Pereira MR, Scully BF, Pouch SM, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2015;21(12):1511–1519. doi:10.1002/lt.24207
   PubMed Web of Science ®Google Scholar
• Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19:1. doi:10.1186/s12967-021-03111-x
   PubMed Web of Science ®Google Scholar
• Chen J, Ma H, Li Y, et al. Risk factors and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary-care hospital in China: an eight-year retrospective study; 2020.
   Google Scholar
• Xiao T, Zhu Y, Zhang S, et al. A retrospective analysis of risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in nontransplant patients. J Infect Dis. 2020;221(Supplement_2):S174–S183. doi:10.1093/infdis/jiz559
   Web of Science ®Google Scholar
• Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140–1145. doi:10.1016/j.ajic.2019.03.003
   PubMed Web of Science ®Google Scholar
• Xie ZY, Meng GL, Xiong Y, et al. Prognostic factors of central venous catheter-related bloodstream infections. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020;42(6):789–794. doi:10.3881/j.issn.1000-503X.12266
   Google Scholar
• Perera D, Kleinstein SE, Hanson B, et al. Impaired host response and the presence of Acinetobacter baumannii in the serum microbiome of type-II diabetic patients. IScience. 2021;24(1):101941. doi:10.1016/j.isci.2020.101941
   Web of Science ®Google Scholar
• Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15–21. doi:10.1097/01.ccm.0000194535
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis. 2012;54(11):1672–1674. doi:10.1093/cid/cis239
   PubMed Web of Science ®Google Scholar
• Niu T, Xiao T, Guo L, et al. Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone&Ndash; Sulbac. Infect Drug Resist. 2018;11:2021–2030. doi:10.2147/IDR.S169432
   PubMed Web of Science ®Google Scholar
• Niu T, Luo Q, Li Y, et al. Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control. 2019;8:1. doi:10.1186/s13756-019-0502-x
   Web of Science ®Google Scholar
• Modemann F, Härterich S, Wiesch JS, et al. Efficacy of tigecycline as salvage therapy in multidrug-resistant febrile neutropenia in patients with acute leukemia—A single center analysis. Antibiotics. 2022;11(2):128. doi:10.3390/antibiotics11020128
   Web of Science ®Google Scholar
• Geng -T-T, Xu X, Huang M. High-Dose Tigecycline for the Treatment of Nosocomial Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections. Medicine. 2018;97(8):e9961. doi:10.1097/MD.0000000000009961
   PubMed Web of Science ®Google Scholar
• Wu Y, Hu Z, Xing L, et al. 替加环素治疗血液病患者继发感染的疗效分析 [Efficacy of tigecycline in treating severe infections of patients with hematological diseases]. Zhonghua Yi Xue Za Zhi. 2014;94(34):2669–2672. Chinese.
   Google Scholar
• Zha L, Pan L, Guo J, et al. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1049–1064. doi:10.1007/s12325-020-01235-y
   PubMed Web of Science ®Google Scholar
• Yu SN, Kim T, Park SY, et al. Predictors of acute kidney injury and 28-day mortality in carbapenem-resistant Acinetobacter baumannii complex bacteremia. Microb Drug Resist. 2021;27(8):1029–1036. doi:10.1089/mdr.2020.0312
   Web of Science ®Google Scholar
• Papadimitriou-Olivgeris M, Assimakopoulos SF, Kolonitsiou F, et al. Risk factors for acute kidney injury in critically ill patients with bacteraemia by carbapenem non-s. Infez Med. 2019;27:380–392.
   Google Scholar
• Freire MP, Garcia D, Garcia CP, et al. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect. 2016;22(4):352–358. doi:10.1016/j.cmi.2015.12.010
   PubMed Web of Science ®Google Scholar
• Huang AH, Liu Y, Hsien Y-C, et al. Survival impact and clinical predictors of acute gastrointestinal bleeding in patients with bloodstream infection. J Intensive Care Med. 2019;36(1):63–69. doi:10.1177/0885066619884896
   Web of Science ®Google Scholar